Corneal topography important to monitor after CXL

Article

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness.

When performing corneal collagen crosslinking (CXL), ophthalmologists should monitor the keratoconus index and the index of height asymmetry garnered from the Scheimpflug camera, because changes in values of these indices are independent from initial corneal thickness. So say researchers from Hungary publishing their work in the Journal of Refractive Surgery.

The researchers, from Hungary, performed CXL in 25 eyes with progressive keratoconus; 25 fellow eyes with nonprogressive keratoconus were the control subjects. The Scheimpflug camera was used to measure thinnest corneal thickness, anterior keratometry (flat, steep) and keratoconus indices before and after CXL (at 12 to 25 months). They assessed the influence of corneal thickness and follow-up time on the flattening effect of CXL using regression analysis.

The investigators found that, at baseline, the eyes that had undergone CXL had significantly higher steep keratometric values and lower thinnest corneal thickness values. These findings were parallel with increased values of the following keratoconus indices: index of surface variance, index of vertical asymmetry, keratoconus index, centre keratoconus index, index of height asymmetry, index of height decentration and radius minimum.

After they adjusted for thinnest corneal thickness and follow-up time, the researchers found that a significant flattening effect was shown with CXL; it was expressed by changes in radius minimum, index of surface variance, keratoconus index, center keratoconus index and index of height asymmetry. Changes of index of surface variance, index of vertical asymmetry and center keratoconus index were significantly influenced by thinnest corneal thickness. Follow-up time had no significant influence in any of the models studied.

To read an abstract of the study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.